-
Study aim
-
1. Detection effect of Montelukast on disease improvement and inflammatory factors in patients with COVID-19
2. Detection effect of Montelukast on duration of hospitalization, changes of interleukin 1 and 6 levels in serum, cough, and oxygen saturation level
-
Design
-
Two arm parallel groups randomized trial with blinded care and outcome assessment.
Randomization: 2 groups A & B
-
Settings and conduct
-
The current study will carry in Ayatollah Rohani hospital -Babol-Iran during 2020. All patients will give standard treatment of COVID-19 disease but test group will take Montelukast (Airokast, Abidi) at dose 10mg per day for at least 10 days along with standard regimen. blood sample will collect at beginning and end of study. The demographic data, fever, coughو and oxygen saturation will record .
biochemical and inflammation markers such as CBC,CRP,LDH, ESR, ALB, TNFα, IL-1, and IL-6 in serum will measure by kits. Lung ct-scan and duration of hospitalization will record.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
1-All hospitalized patients with confirmed COVID-19 at both gender and 18-90 ages include in this study
2-All hospitalized patients with confirmed COVID-19 without other severe disease
3-Patient consent
Exclusion criteria:
1-Patients with suspected COVID-19
2-History of allergy to Montelukast
3-lack of cooperation from the patient
-
Intervention groups
-
114 patients with COVID-19 will divide two groups (57 patients each group): group1: standard regimen; group2: standard regimen+ Montelukast
-
Main outcome variables
-
Primary outcomes:CBC,CRP,LDH وESR و ALB و IL-1,IL-6